MedPath

The Endocrine Colon in Humans

Not Applicable
Conditions
Healthy
Interventions
Other: Lactulose
Other: Placebo (water)
Other: Picoprep
Registration Number
NCT04159181
Lead Sponsor
University of Copenhagen
Brief Summary

This study will examine the role of the colon as an endocrine organ with a focus on the secretion of gastrointestinal peptides.

Detailed Description

This study will examine the role of the colon as an endocrine organ with a focus on the secretion of gastrointestinal peptides.

We aim to determine the contribution of the colon to the fasting and postprandial release of gut peptides such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Young healthy men will be examined on three occasions at a clinical research Facility after an overnight fast. On one occasion the colon will also be emptied using a cathartic (picoprep). On two occasions an oral solution of lactulose will be administered to stimulate fermentation by colonic bacteria.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
10
Inclusion Criteria
  • Healthy young men (self-reported)
  • BMI between 18,5-24,9 kg/m^2
Exclusion Criteria
  • Diabetes mellitus (elevated fasting plasma glucose or HbA1c)
  • Family history of diabetes mellitus
  • Intestinal disease (e.g. inflammatory bowel disease, malabsorption)
  • Family history of intestinal diseases
  • Previous gastrointestinal surgery
  • BMI >25 kg/m^2
  • Tobacco use
  • Alcohol consumption > 14 standard drinks/week
  • Drug use
  • Kidney, Heart- or Liver disease
  • Treatment with prescription drugs that can not be held for 12h
  • Constipation
  • Accelerated or delayed gastric emptying
  • Absence of daily bowel movements
  • Vegetarian lifestyle
  • > than 3kgs weightloss or weight gain within 3 months
  • Haemoglobin concentration < 8,0mmol/L
  • Bleeding diathesis
  • Latex or bandaid allergies

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Day CLactuloseAfter an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
Day BPlacebo (water)After an overnight fast participants will drink 200mL of water
Day CPicoprepAfter an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
Day ALactuloseAfter an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).
Primary Outcome Measures
NameTimeMethod
GLP-1-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Plasma concentrations of glucagon-like peptide-1 (GLP-1)

Secondary Outcome Measures
NameTimeMethod
PYY-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Plasma concentrations of peptide YY (PYY)

Ghrelin-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Plasma concentrations of ghrelin

Glucagon-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Plasma concentrations of glucagon

Motilin-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Plasma concentrations of motilin

Hydrogen breath test-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Concentrations of hydrogen in exhaled air

Neurotensin-60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min

Plasma concentrations of Neurotensin

Trial Locations

Locations (2)

Hvidovre University Hospital

🇩🇰

Hvidovre, Capital, Denmark

University of Copenhagen

🇩🇰

Copenhagen, Capital, Denmark

© Copyright 2025. All Rights Reserved by MedPath